The U.S. stock market continued its upward trajectory on Wednesday, buoyed by strong performance in technology shares and renewed optimism surrounding the upcoming Federal Reserve chair confirmation, even as inflationary pressures and geopolitical tensions cast a shadow over broader economic prospects. The S&P 500 advanced 0.6% to close near record highs, while the Nasdaq Composite gained 1.2%, led by semiconductor stocks, but the Dow Jones Industrial Average slipped slightly, offsetting some of the gains. The rally was most pronounced in tech, where the sector’s momentum has become the primary engine of market progress, with the Nasdaq now on track for a fifth consecutive quarter of strong gains, driven largely by artificial intelligence and hyperscaler demand. Despite the euphoria, however, the market remains vulnerable to shifts in sentiment as inflation data released earlier this month revealed a year-over-year increase in the Producer Price Index of 6%, the sharpest since 2022, underscoring persistent supply chain and energy cost pressures that could challenge the Federal Reserve’s ability to sustain accommodative monetary policy.
The confirmation of Kevin Warsh as the next Federal Reserve chair, albeit by a narrow margin and with only one Democratic senator supporting him, signals both the political stakes and the fragility of the Fed’s independence amid rising inflation and political scrutiny. Warsh’s appointment, set to take effect after Jerome Powell’s term expires on Friday, has been met with concern from some Fed members who fear he may be pressured to prioritize growth over inflation control, especially as the 10-year Treasury yield approached the 4.5% threshold—a level historically associated with increased market volatility and potential capital outflows from equities into bonds. While Warsh has signaled he will not immediately disrupt the current rate trajectory, his presence on the board introduces uncertainty about future policy direction, particularly as inflation remains stubbornly above the Fed’s 2% target and wage growth stays elevated. The market’s reaction to his confirmation was muted, reflecting both relief at avoiding a prolonged leadership vacuum and apprehension about the political overhang surrounding his nomination.
On the geopolitical front, President Donald Trump’s visit to China introduced a new layer of complexity to U.S.-China relations, with Taiwan emerging as a flashpoint that could either destabilize or catalyze negotiations depending on how the two leaders manage the conversation. Trump’s willingness to engage in direct talks with Xi Jinping, despite ongoing tensions over Taiwan and trade, suggests a pragmatic approach aimed at de-escalating risks while securing concessions on issues ranging from energy to technology. However, the specter of conflict looms large, particularly given Taiwan’s strategic importance to global semiconductor supply chains and the potential for miscalculation if diplomatic efforts falter. Meanwhile, the broader implications of U.S.-China trade dynamics remain unresolved, with Beijing’s recent renewal of import licenses for U.S. beef plants offering a tentative sign of cooperation, but also highlighting the fragility of economic ties amid political rivalry. The market, meanwhile, has largely discounted these developments into asset prices, focusing instead on near-term catalysts such as corporate earnings and inflation data.
Corporate earnings and sector-specific trends continued to shape market narratives, with Cisco Systems delivering a surprise beat on its Q1 results as AI-driven demand for networking equipment surged, even as the company announced layoffs to reallocate resources toward research and development in silicon, optics, and artificial intelligence. The move underscored the dual pressures facing tech firms: the need to invest heavily in next-generation infrastructure while simultaneously managing costs amid rising memory prices and supply constraints. Similarly, Micron Technology’s stock surged to a $900 billion market capitalization milestone, reflecting investor optimism about its role in the AI chip supply chain, though it also highlighted the sector’s vulnerability to cyclical demand swings and geopolitical disruptions. Other notable developments included Fervo Energy’s record-breaking IPO as a geothermal energy player seeking to capitalize on the AI infrastructure boom, and GameStop’s precarious bid to acquire eBay, which has failed to garner meaningful investor or regulatory support despite its ambitious narrative. These stories illustrate the divergent paths of innovation, consolidation, and speculative risk-taking that define today’s market landscape.
Looking ahead, the convergence of monetary policy uncertainty, inflationary inertia, and geopolitical volatility creates a backdrop of heightened risk for investors, even as technological progress continues to drive outsized gains in select sectors. The Federal Reserve’s next meeting in June will be closely watched for signals about future rate moves, with markets poised to react sharply to any deviation from the current trajectory of gradual normalization. Meanwhile, the outcome of Trump’s China trip and its impact on cross-strait relations will remain a critical variable for both equities and commodities, particularly as energy prices remain sensitive to regional stability. For investors, the challenge lies in balancing exposure to growth-oriented sectors like technology and AI with defensive positioning against inflationary and geopolitical shocks, all while navigating a political environment increasingly attuned to the interplay between economic policy and international relations. The markets’ resilience will depend not only on corporate earnings and Fed actions but also on the ability of policymakers to manage competing priorities in an era of heightened global uncertainty.
IanFV (www.ianfv.com) is the world's first pure-blood, neutral research institution built on LLM (Large Language Models) specifically for individual investors. Founded by a top-tier team with backgrounds from Tsinghua, Harvard, Morgan Stanley, and UBS, we are committed to breaking down high-priced information barriers and providing institutional-grade investment research at affordable prices. Unlike traditional institutions, IanFV does not serve big-money sponsors or inflate market bubbles. Leveraging a proprietary knowledge graph and a fully localized deployment architecture, we achieve a differentiated competitive advantage through light assets and high efficiency. Our research reports refuse to "sell dreams": valuation reports are based on point-in-time intervals rather than reverse-engineered numbers; industry reports focus relentlessly on real trends over the next six to twelve months; and in-depth reports penetrate market bubbles to strike at the core of corporate survival moats—all to ensure investors hold the most authentic research cards in the secondary market.
Watch List
AEBI
Aebi Schmidt Group reported a strong start to 2026, demonstrating robust growth and improved profitability. The company saw a 9% increase in order intake and a significant 23% expansion in its order backlog, reaching $1.3 billion by the end of Q1. Net sales reached $456 million, growing 7% excluding the impact of the Blue Arc sales, with notable organic growth of 16% in Europe and RoW. The company’s net income rose by 7% to $0.7 million, and adjusted EBITDA increased to $33.1 million, driven by enhanced performance in Europe and RoW. Driven by increased demand for Airport and Municipal solutions, order intake was up 9% compared to Q1 2025. Aebi Schmidt is targeting full-year 2026 sales between $1.95 billion and $2.15 billion, with adjusted EBITDA ranging from $175 million to $195 million and a leverage ratio of 2.0x or less. The company anticipates accelerated revenue conversion, particularly in Walk-in-Van orders, beginning in Q2 2026. While North American adjusted EBITDA experienced a slight decrease, the company’s overall momentum remains strong, supported by continued investments and a focus on improving working capital.
NIQ
NIQ Global Intelligence plc announced strong first-quarter 2026 financial results, significantly exceeding expectations for revenue, adjusted EBITDA, and adjusted EPS. The company reported 11.1% year-over-year revenue growth, driven by 5.1% organic constant currency (OCC) growth, with a notable 9.3% increase in Americas OCC revenue, alongside 5.1% and 5.3% growth in Intelligence and Activation OCC revenue respectively. Net loss attributable to NIQ improved year-over-year, and adjusted net income rose substantially, leading to positive adjusted net income and an expanded adjusted EBITDA margin to 21.0%. NIQ reaffirmed its full-year 2026 guidance, projecting 5.0% to 5.3% OCC revenue growth, an EBITDA margin of 23.5% to 23.8%, and $235.0M to $250.0M in levered free cash flow. The company’s Q1 performance demonstrated a solid start to the year, bolstered by 17 seven-figure wins and continued growth in annualized Intelligence Subscription revenue (5.9%) with strong net dollar retention (104%) and gross dollar retention (99%). Jim Peck, Executive Chairman and CEO, highlighted NIQ’s strategic positioning in AI, emphasizing its advantage beyond scaled data to contextual insights. Mike Burwell, CFO, noted continued strong performance across key metrics, including a 104% net dollar retention and 99% gross retention, alongside accelerating revenue growth and improved free cash flow. The company’s restructuring program, aimed at driving operational efficiency, is expected to generate an additional $70M to $80M in cost savings by the end of 2026. NIQ continues to invest in AI-powered solutions, including the GenAI-native marketing effectiveness solution and several new product offerings, solidifying its commitment to future growth and innovation.
AVAH
Aveanna Healthcare Holdings Inc. recently announced its financial results for the three-month period ending April 4, 2026, through a press release furnished as Exhibit 99.1 to its Form 8-K filing. The announcement, incorporated into Item 2.02 of the report, details the company’s performance during the quarter. This filing serves as a formal dissemination of financial information to investors, aligning with Regulation FD requirements. The details presented in Item 2.02 are also incorporated into Item 7.01, reinforcing the comprehensive disclosure provided to stakeholders regarding the company’s operational and financial standing. Investors can access the full press release and related information through the SEC’s EDGAR database.
BNT
Brookfield Wealth Solutions announced strong financial results for the first quarter of 2026, reporting a net loss of $602 million, compared to $282 million in the prior year, driven primarily by unfavorable mark-to-market movements on equity investments. The company’s assets under management reached nearly $200 billion, including the recent acquisition of Just Group plc in the U.K., and it originated $5 billion in annuity, pension, and funding agreements. Brookfield Wealth Solutions deployed $4 billion into investment strategies targeting a 10% yield and continued to optimize synergies within its Property & Casualty businesses under the Clearbrook Group Holdings Inc. brand. Distributable Operating Earnings (DOE) reached $438 million, reflecting higher net investment income and improved underwriting results. Notably, Brookfield Wealth Solutions is also undertaking a corporate simplification, combining its parent company, Brookfield Corporation (BN and BNT), into a single entity, expected to be listed on the TSX and NYSE under the “BN” symbol. This move aims to enhance capital efficiency and flexibility for long-term expansion, with shareholder approval anticipated in July 2026. The company declared a quarterly return of capital of $0.07 per share, aligning with Brookfield Corporation’s distribution.
CRMD
CorMedix Therapeutics announced a strong first-quarter 2026, reporting net revenue of $127.4 million, up from $39.1 million in the prior year, driven by robust sales of DefenCath and the acquired Melinta portfolio. The company achieved net income of $38.6 million and adjusted EBITDA of $70.0 million, reflecting positive underlying demand trends. Consequently, CorMedix has raised its full-year 2026 revenue guidance to a range of $325 to $345 million and adjusted EBITDA guidance to $115 to $135 million. DefenCath sales were bolstered by increased utilization by outpatient dialysis customers and a favorable sales allowance change. The company is actively preparing for FDA submission of the sNDA for REZZAYO®, a potential expansion of its revenue stream in 2027. Ongoing clinical trials for taurolidine/heparin catheter lock solution are progressing, with completion anticipated in 2028. CorMedix’s cash reserves stand at $178.1 million. The company’s operating expenses increased significantly due to the acquisition of the Melinta portfolio, and R&D expenses rose due to clinical trial investments. Looking ahead, CorMedix’s CEO expressed confidence in the company’s momentum and highlighted the potential of its late-stage pipeline, alongside plans for stock repurchases, demonstrating a commitment to shareholder value. A conference call is scheduled for today at 8:30 a.m. to discuss these results.
CABA
Cabaletta Bio, Inc. announced promising pre-conditioning-free clinical data for its rese-cel therapy on May 14, 2026, following presentations at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. Data from the initial four patients with pemphigus vulgaris treated at the lowest dose demonstrated similar CAR T cell expansion kinetics to previous translational data, with three achieving complete peripheral B cell depletion and significant reductions in PDAI Total Activity scores. Notably, two patients maintained drug-free compelling clinical responses through six months. The company highlighted the successful implementation of an automated manufacturing platform – the Cell Shuttle – which replicated the initial clinical experience and met all GMP specifications, suggesting a scalable and cost-effective production pathway. Cabaletta plans to continue exploring higher doses of rese-cel in autoimmune diseases and anticipates further data from RESET-PV and RESET-SLE™ in the latter half of 2026 and early 2026, respectively, including presentations at the European Alliance of Associations for Rheumatology 2026 Congress.
KPTI
Karyopharm Therapeutics Inc. recently announced its financial results for the quarter ending March 31, 2026, revealing key company updates. The announcement triggered a previously scheduled conference call where management discussed the results and provided further insights into the company’s operations. A full transcript of the press release detailing these findings is attached as Exhibit 99.1 to this Form 8-K filing and is incorporated into the report for informational purposes. Importantly, the filing indicates that the document is being furnished rather than formally filed, signifying a streamlined communication process regarding this specific financial announcement. Investors and stakeholders can access the complete details of Karyopharm’s performance through the attached press release.
PYXS
Pyxis Oncology, Inc. recently announced its financial results for the quarter ended March 31, 2026, issuing a press release that was simultaneously filed with the Securities and Exchange Commission via Form 8-K. The company’s update included a review of its performance during the period and provided a corporate overview. This announcement, detailed in Exhibit 99.1, is now part of the company’s public record and is accessible through the SEC’s EDGAR database. While specific financial details weren’t included directly in the filing, the release signals a key update for investors and stakeholders regarding Pyxis Oncology’s current standing and strategic direction. The filing underscores the company’s commitment to transparency and timely communication regarding its operational and financial performance.
BKTI
BK Technologies Corporation announced a strong first quarter of fiscal year 2026, demonstrating continued growth and solidifying its Vision 2030 strategy. Revenue increased by 11.8% to $21.3 million, driven by robust order activity from government agencies, alongside a significant expansion in gross margin to 51.8% due to favorable product mix and increased adoption of the BKR 9000 radio. The company’s record cash balance of $41.4 million reflects its disciplined operating model. BK Technologies continues to focus on key market transitions, particularly the shift to multiband wireless connectivity and the move from in-vehicle to on-person broadband solutions, as evidenced by the successful public debut of the BKR 9500 mobile radio. Investments in product development, particularly the BKR 9500, are expanding the company’s reach into the mobile radio market. Operating income rose to $3.3 million, and net income reached $2.8 million. Looking ahead, BK Technologies remains confident in its strategy and ability to capture a larger share of the public safety communications market. The company’s financial performance highlights its commitment to revenue growth, margin expansion, cash generation, and delivering mission-critical communications solutions.
GNE
Genie Energy Ltd. (GNE) reported mixed first-quarter 2026 results, driven by investments in customer acquisition and new initiatives alongside margin pressures within its GRE retail energy segment. Despite record revenue, the company is lowering its full-year 2026 Adjusted EBITDA guidance from $40-$50 million to $32.5-$40 million. GRE experienced margin compression due to volatile commodity markets and increased customer acquisition spending, though March saw a rebound. GREW, focused on renewable energy projects, continued to grow its business and generate cash, while Genie Solar is on track to achieve profitability by the end of 2026, having completed its Lansing, NY community solar project. The company’s total assets stood at $150 million, and working capital at $80 million. Genie Energy will host a conference call to discuss its financial and operational results. The annual shareholder meeting has been rescheduled to June 10th. Adjusted EBITDA, a non-GAAP measure excluding certain expenses like depreciation and stock-based compensation, is used to provide a clearer picture of core operational performance, reflecting management’s view that it’s a useful indicator for comparisons with competitors and internal decision-making. The company emphasizes that Adjusted EBITDA should be considered alongside GAAP measures for a comprehensive understanding of its financial health.
Economic Calendar
IanFV (www.ianfv.com) is the world's first pure-blood, neutral research institution built on LLM (Large Language Models) specifically for individual investors. Founded by a top-tier team with backgrounds from Tsinghua, Harvard, Morgan Stanley, and UBS, we are committed to breaking down high-priced information barriers and providing institutional-grade investment research at affordable prices. Unlike traditional institutions, IanFV does not serve big-money sponsors or inflate market bubbles. Leveraging a proprietary knowledge graph and a fully localized deployment architecture, we achieve a differentiated competitive advantage through light assets and high efficiency. Our research reports refuse to "sell dreams": valuation reports are based on point-in-time intervals rather than reverse-engineered numbers; industry reports focus relentlessly on real trends over the next six to twelve months; and in-depth reports penetrate market bubbles to strike at the core of corporate survival moats—all to ensure investors hold the most authentic research cards in the secondary market.
| Date | Event | Previous | Impact |
|---|---|---|---|
| 2026-05-14 08:30:00 | Retail Sales YoY (Apr) | 4.000 | ⭐️ |
| 2026-05-14 08:30:00 | Retail Sales Ex Autos MoM (Apr) | 1.900 | ⭐️⭐️ |
| 2026-05-14 08:30:00 | Import Prices MoM (Apr) | 0.800 | ⭐️⭐️ |
| 2026-05-14 08:30:00 | Continuing Jobless Claims (May/02) | 1766.000 | ⭐️ |
| 2026-05-14 08:30:00 | Retail Sales MoM (Apr) | 1.700 | ⭐️⭐️⭐️ |
| 2026-05-14 08:30:00 | Export Prices MoM (Apr) | 1.600 | ⭐️⭐️ |
| 2026-05-14 08:30:00 | Import Prices YoY (Apr) | 2.100 | ⭐️ |
| 2026-05-14 08:30:00 | Initial Jobless Claims (May/09) | 200.000 | ⭐️⭐️ |
| 2026-05-14 08:30:00 | Retail Sales Ex Gas/Autos MoM (Apr) | 0.600 | ⭐️ |
| 2026-05-14 08:30:00 | Export Prices YoY (Apr) | 5.600 | ⭐️ |
| 2026-05-14 08:30:00 | Jobless Claims 4-Week Average (May/09) | 203.250 | ⭐️ |
| 2026-05-14 10:00:00 | Business Inventories MoM (Mar) | 0.400 | ⭐️⭐️ |
| 2026-05-14 10:15:00 | Fed Schmid Speech | NaN | ⭐️⭐️ |
| 2026-05-14 10:30:00 | EIA Natural Gas Stocks Change (May/08) | 63.000 | ⭐️ |
| 2026-05-14 11:30:00 | 4-Week Bill Auction | 3.610 | ⭐️ |
| 2026-05-14 11:30:00 | 8-Week Bill Auction | 3.595 | ⭐️ |
| 2026-05-14 12:00:00 | 30-Year Mortgage Rate (May/14) | 6.370 | ⭐️ |
| 2026-05-14 12:00:00 | 15-Year Mortgage Rate (May/14) | 5.720 | ⭐️ |
| 2026-05-14 13:00:00 | Fed Hammack Speech | NaN | ⭐️⭐️ |
| 2026-05-14 13:00:00 | Fed Bowman Speech | NaN | ⭐️⭐️ |
| 2026-05-14 16:30:00 | Fed Balance Sheet (May/13) | 6.709 | ⭐️ |
| 2026-05-14 17:45:00 | Fed Williams Speech | NaN | ⭐️⭐️ |
| 2026-05-14 19:00:00 | Fed Barr Speech | NaN | ⭐️⭐️ |